Trial Profile

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 May 2021 Number of treatment arms are reduced from 3 to 1, by removing experimental part 2, retaining only the experimental dose finding arm. Phase is changed from 1/2 to 1 and study design is changed from randomized, double-blind to open label. Primary efficacy end-point is removed, thus removing "TU" from trial focus.
10 May 2021 Status changed from recruiting to completed.
07 Jan 2021 This trial has been Discontinued in Hungary, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com